SCHEMBL6071815

SCHEMBL6071815

CCOc1cc2c(c3c1OC(C)(C)C3)C(c1ccc(C(=O)O)c(NC(C)=O)c1)=NC(C)(C)C2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KMT2A Q03164 2/20 0.34
HPGD P15428 1/20 0.34
POLB P06746 1/20 0.34
IDO1 P14902 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
STK4 Q13043 3/20 0.33
CREBBP Q92793 1/20 0.32
MAPT P10636 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
IRAK4 Q9NWZ3 2/20 0.31
TSHR P16473 1/20 0.31
HTT P42858 1/20 0.31
ATM Q13315 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
SSTR5 P35346 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6072201 0.93 TDP1 (0.39) SMN1; SMN2MEN1ALDH1A1KMT2APOLB
SCHEMBL6072284 0.92 IDO1 (0.33) SMN1; SMN2MEN1ALDH1A1KMT2AIDO1
SCHEMBL6072447 0.91 IDO1 (0.33) IDO1IRAK4
SCHEMBL6072931 0.91 HDAC1 (0.39) SMN1; SMN2MEN1ALDH1A1KMT2AHPGD
SCHEMBL6072762 0.90 IDO1 (0.32) ALDH1A1IDO1MAPTSSTR5
SCHEMBL6072219 0.90 SMN1; SMN2 (0.39) SMN1; SMN2MEN1ALDH1A1KMT2APOLB
SCHEMBL6072322 0.90 PDE10A (0.32) IDO1
SCHEMBL6072217 0.89 CREBBP (0.38) SMN1; SMN2MEN1ALDH1A1KMT2AHPGD
SCHEMBL6072317 0.89 IDO1 (0.31) IDO1SSTR5
SCHEMBL6072777 0.89 AKR1C3 (0.35) SMN1; SMN2MEN1ALDH1A1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060106048-A1 Furoisoquinoline derivative and use thereof PASCALI, PETROS P. (CY) 2006-05-18 US disclosed
EP-1541576-A1 FUROISOQUINOLINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106048-A1 Furoisoquinoline derivative and use thereof PDE3B, PDE2A, PDE3A SMN1; SMN2 4490/4885MEN1 1942/4885ALDH1A1 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.